Physician profile
Mary Suarez
NPI 1588393953
$6,556.10
in general payments reported to CMS, 2019-2025
30 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $434 · 2023: $2,232 · 2024: $1,972 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,748 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,747.58 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $897.21 | 2022-2025 | Myrisk, Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $833.43 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $704.16 | 2022-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $487.42 | 2022-2025 | Pylarify |
| Blue Earth Diagnostics | $482.74 | 2023-2025 | Posluma |
| Sumitomo Pharma America, INC. | $438.62 | 2023-2025 | Orgovyx |
| Astrazeneca Pharmaceuticals Lp | $381.64 | 2022-2025 | Lynparza |
| Janssen Scientific Affairs, LLC | $375.00 | 2025 | Erleada |
| Pfizer INC. | $288.11 | 2022-2025 | |
| Janssen Biotech, INC. | $229.89 | 2022-2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $196.41 | 2023-2025 | |
| Astellas Pharma US INC | $195.49 | 2023-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $133.02 | 2023-2025 | Lynparza, Welireg, Keytruda |
| Abbvie INC. | $126.20 | 2023-2024 | |
| Boston Scientific Corporation | $112.51 | 2022-2023 | Spaceoar Vue System - 10ml |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $96.69 | 2024-2025 | Eligard |
| Insmed, INC. | $88.82 | 2024 | Arikayce |
| Sun Pharmaceutical Industries INC. | $74.05 | 2022-2025 | Yonsa |
| Novocure INC. | $67.28 | 2024-2025 | Optune Gio, Optune |
| Teleflex LLC | $63.55 | 2023-2025 | Urolift, Barrigel |
| Foundation Medicine, INC. | $60.47 | 2023 | |
| Caris Mpi, INC. | $50.17 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $34.35 | 2025 | Libtayo |
| Menarini Silicon Biosystems, INC. | $27.19 | 2023 | Cellsearch |
| Janssen Pharmaceuticals, INC | $23.77 | 2024 | Xarelto |
| Bioprotect Medical, INC. | $22.01 | 2025 | Bioprotect Balloon Implant System |
| Myovant Sciences INC. | $20.80 | 2022 | |
| Axonics, INC. | $16.21 | 2023 | Axonics |
| Kyowa Kirin, INC. | $14.87 | 2022 | |
| Accord Healthcare, INC. | $14.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.